



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**HYDROMORPHONE ER**

Generic	Brand	HICL	GCN	Exception/Other
HYDROMORPHONE ER	EXALGO		22056 28427 22098 33088	EXTENDED RELEASE ONLY

**GUIDELINES FOR USE**

1. Does the patient meet the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day, or an equianalgesic dose of another opioid)?

If yes, continue to #2.

If no, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

2. Does the request form indicate that this medication will be used on an "as needed" or "PRN" basis?

If yes, do not approve.

**DENIAL TEXT:** See the denial text at the end of the guideline.

If no, continue to #3.

3. Does the patient require a dosage of 16mg or less?

If yes, **approve for 12 months by GPID (8mg, 12mg, 16mg) for #1 tablets per day. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).**

If no, continue to #4.

4. Was this dosage recommended by a pain specialist?

If yes, **approve for 12 months by GPID (32mg) for #2 tablets per day. (NOTE: Please override both PA and step therapy [if applicable] restrictions by entering 'Y' for OVR\_RES).**

If no, do not approve.

**DENIAL TEXT:** The guideline named **HYDROMORPHONE ER** requires that the patient meets the following criteria:

- The patient meets the definition of opioid tolerance (defined as those who are taking, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 25 mg oral oxymorphone/day, 8 mg oral hydromorphone/day), or an equianalgesic dose of another opioid)
- The requested medication is not prescribed on an 'as needed' basis
- Dosages above 16mg require recommendation by a pain specialist

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

HYDROMORPHONE ER

**RATIONALE**

For further information, please refer to the Prescribing Information and/or Drug Monograph for Exalgo.

**REFERENCES**

- Exalgo [Prescribing Information]. Hazelwood, MO: Mallinckrodt; April 2014.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 10/01/19

Created: 04/10

Client Approval: 08/19

P&T Approval: 07/19